MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 117-125

  Tentori, Lucio ^a   Muzi, Alessia ^a   Dorio, Annalisa Susanna ^a   Dolci, Susanna ^a   Campolo, Federica ^a   Vernole, Patrizia ^a   Lacal, Pedro Miguel ^b   Praz, Françoise ^c,d   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Chemotherapy; Colon cancer; DNA repair; Drug resistance; Mismatch repair; Poly(ADP ribose) polymerase

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEIC ACID BINDING PROTEIN; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN MLH1; PROTEIN MSH3; PROTEIN P53; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM COMPLEMENTATION GROUP F PROTEIN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; CHROMOSOME 3; CHROMOSOME 5; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MLH1 GENE; MONOTHERAPY; MSH3 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CODON, NONSENSE; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FRAMESHIFT MUTATION; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MUTANT PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84879775148     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2175-0     Document Type: Article

References (27)

1. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886
2. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585
3. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291-1295. doi: 10.1158/1078-0432. CCR-07-2238
4. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123-131
5. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193-5201
6. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875. doi: 10.1093/jnci/djr153
7. Plaschke J, Krüger S, Jeske B, Theissig F, Kreuz FR, Pistorius S, Saeger HD, Iaccarino I, Marra G, Schackert HK (2004) Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res 64:864-870. doi: 10.1158/0008-5472.CAN-03- 2807
8. Plaschke J, Preußler M, Ziegler A, Schackert HK (2012) Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability. Int J Colorectal Dis 27:911-919
9. Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI (2001) Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 20:4640-4649
10. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2:2512-2519. doi: 10.1200/JCO.2009.26.9589
11. Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC (2012) BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 125:677-682. doi: 10.1016/j.ygyno.2012.03.006
12. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917. doi: 10.1038/nature03443
13. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921. doi: 10.1038/nature03445
14. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS (2011) Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10:1192-1199
15. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A (2011) MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 286:12157-12165. doi: 10.1074/jbc.M110.198804
16. Papadopoulos N, Nicoladesi NC, Wei YF, Ruben SM, Carte KC, Rosen CA, Haseltine WA, Fleishmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen P, Watson GM, Lynch HT, Peltomaki P, Mecklin JP, de la Chapelle A, Kinzler KW, Vogelstein B (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625-1629
17. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, Nagasaka T, Kanazawa S, Koike J, Kikuchi Y, Zhong X, Arita M, Shibuya K, Oshimura M, Hemmi H, Boland CR, Koi M (2008) Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 68:8465-8472. doi: 10.1158/0008-5472.CAN-08-0002
18. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54:4308-4312
19. Jacob S, Aguado M, Fallik D, Praz F (2001) The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 61:6555-6562
20. Marra G, Iaccarino I, Lettieri T, Roscilli G, Delmastro P, Jiricny J (1998) Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA 95:8568-8573
21. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9:5370-5379
22. Yamane K, Taylor K, Kinsella TJ (2004) Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Commun 318:297-302
23. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079-17084. doi: 10.1073/pnas.0806092105
24. Zhu G, Chang P, Lippard SJ (2010) Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. Biochemistry 49:6177-6183. doi: 10.1021/bi100775t
25. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB (2011) MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71:2632-2642. doi: 10.1158/0008-5472.CAN-10-1120
26. Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J (2012) Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11:3837-3850. doi: 10.4161/cc.22026
27. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389-5398. doi: 10.1158/0008-5472.CAN-09-4716